Literature DB >> 7831795

Structure and biological activity of the subgenomic Mtv-6 endogenous provirus.

K Cho1, D A Ferrick, D W Morris.   

Abstract

The Mtv-6 provirus has an incomplete genome, but retains a functional superantigen gene (sag) which directs the thymic deletion of CD4+ T cells expressing T cell receptors containing the V beta 3 or V beta 5 chains. To better understand the Mtv-6 superantigen, the structure and biological activity of the Mtv-6 provirus was analyzed. First, the complete nucleotide sequence was determined, and the mutation producing the subgenomic provirus was identified. Second, the nucleotide sequence of the 5' end of the sag gene transcript (including the splice junction) was determined by sequence analysis of a cDNA clone. Third, the superantigen activity of Mtv-6 was analyzed in mice carrying the Mtv-6 provirus isolated by selective breeding on a genetic background free of endogenous and exogenous mouse mammary tumor virus (MMTV). These studies demonstrate that (i) the Mtv-6 provirus contains a 6.2-kb deletion between two 12-bp direct repeats encompassing the central portion of the provirus but not affecting sag gene splicing or translation, (ii) the sag gene transcript has the structure predicted from previous S1 nuclease mapping studies, and (iii) the Mtv-6 superantigen can direct thymic deletion of target V beta 3+ and V beta 5+ T cells in the absence of gene products from full-length MMTV proviruses.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7831795     DOI: 10.1016/s0042-6822(95)80055-7

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  12 in total

1.  Sequence and genetic analyses of the 3' terminus and integration sites of the RIII/Sa mouse mammary tumor (MMTV) exogenous provirus.

Authors:  P Popken-Harris; L Pliml; L Harris
Journal:  Virus Genes       Date:  2001       Impact factor: 2.332

2.  C3H mouse mammary tumor virus superantigen function requires a splice donor site in the envelope gene.

Authors:  F Mustafa; M Lozano; J P Dudley
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

3.  Viral superantigen drives extrafollicular and follicular B cell differentiation leading to virus-specific antibody production.

Authors:  S A Luther; A Gulbranson-Judge; H Acha-Orbea; I C MacLennan
Journal:  J Exp Med       Date:  1997-02-03       Impact factor: 14.307

4.  A novel V beta 2-specific endogenous mouse mammary tumor virus which is capable of producing a milk-borne exogenous virus.

Authors:  N Niimi; W Wajjwalku; Y Ando; N Nakamura; M Ueda; Y Yoshikai
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

5.  Mouse mammary tumor virus superantigen expression in B cells is regulated by a central enhancer within the pol gene.

Authors:  F U Reuss; J M Coffin
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

6.  The homeodomain protein CDP regulates mammary-specific gene transcription and tumorigenesis.

Authors:  Quan Zhu; Urmila Maitra; Dennis Johnston; Mary Lozano; Jaquelin P Dudley
Journal:  Mol Cell Biol       Date:  2004-06       Impact factor: 4.272

7.  BALB/Mtv-null mice responding to strong mouse mammary tumor virus superantigens restrict mammary tumorigenesis.

Authors:  Sanchita Bhadra; Mary M Lozano; Jaquelin P Dudley
Journal:  J Virol       Date:  2008-10-15       Impact factor: 5.103

8.  Stimulation of mouse mammary tumor virus superantigen expression by an intragenic enhancer.

Authors:  F U Reuss; J M Coffin
Journal:  Proc Natl Acad Sci U S A       Date:  1995-09-26       Impact factor: 11.205

9.  Endogenous MMTV proviruses induce susceptibility to both viral and bacterial pathogens.

Authors:  Sanchita Bhadra; Mary M Lozano; Shelley M Payne; Jaquelin P Dudley
Journal:  PLoS Pathog       Date:  2006-12       Impact factor: 6.823

Review 10.  Endogenous mouse mammary tumor viruses (mtv): new roles for an old virus in cancer, infection, and immunity.

Authors:  Michael P Holt; Ethan M Shevach; George A Punkosdy
Journal:  Front Oncol       Date:  2013-11-26       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.